WikiJournalClub:List of landmark papers/Cardiology

From Wiki Journal Club

< WikiJournalClub:List of landmark papers

Contents
1 Hypertension
2 Stable CAD
2.1 PCI/CABG
2.2 RAAS inhibition
3 Acute Coronary Syndrome
3.1 Antiplatelets
3.2 Anticoagulation
3.3 -blockers
3.4 GPIIb/IIIa Inhibitors
3.5 PCI/CABG
3.6 Lytics
3.7 RAAS inhibitors
3.8 Statins
3.9 ICD/CRT
3.10 Risk Assessment
4 Atrial Fibrillation
4.1 Epidemiology
4.2 Management
4.3 Antiarrhythmics
4.4 Anticoagulation
5 CHF
5.1 Hydralazine & nitrates
5.2 -blockers
5.3 Ace-inhibitors
5.4 ARBs
5.5 Aldosterone antagonists
5.6 Digoxin
5.7 ICD
5.8 Volume management
5.9 Nesiritide
5.10 LVAD
5.11 Fish oil
5.12 Telemonitoring
6 Cardiac Risk Assessment
7 Endocarditis

Hypertension
1967 VA Cooperative Study htn control reduces morbidity [1] (http://www.ncbi.nlm.nih.gov/pubmed/4862069)
2001 DASH DASH diet with differen sodium levels and bp results [2]
(http://www.nejm.org/doi/full/10.1056/NEJM200101043440101)
1992 TOHP I lifestyle interventions in prehypertension [3] (http://www.ncbi.nlm.nih.gov/pubmed/1586398)
1997 TOHP II sodium interventions in prehypertension [4] (http://www.ncbi.nlm.nih.gov/pubmed/9080920)
2008 HYVET BP treatment in elderly [5] (http://www.nejm.org/doi/full/10.1056/NEJMoa0801369)

Stable CAD
PCI/CABG
2007 COURAGE PCI vs. OMT in stable CAD [6] (http://www.nejm.org/doi/full/10.1056/NEJMoa070829)
2009 BARI 2D PCI or CABG vs. OMT in T2DM and stable CAD [7] (http://www.nejm.org/doi/full/10.1056/NEJMoa0805796)
2009 FAME FFR in PCI [8] (http://www.nejm.org/doi/full/10.1056/NEJMoa0807611)
2009 SYNTAX PCI vs. CABG in LM/3VD [9] (http://www.nejm.org/doi/full/10.1056/NEJMoa0804626)
2011 STICH CABG vs. OMT in LV dysfunction [10] (http://www.nejm.org/doi/full/10.1056/NEJMoa1100356)
2012 FREEDOM CABG vs. PCI in DM [11] (http://www.nejm.org/doi/full/10.1056/NEJMoa1211585)
RAAS inhibition
2000 HOPE Ramipril in high-risk patients [12] (http://www.nejm.org/doi/full/10.1056/NEJM200001203420301)
2003 EUROPA Perindopril in stable CAD [13] (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)142869/fulltext)
2004 PEACE Trandolapril in stable CAD [14] (http://www.nejm.org/doi/full/10.1056/NEJMoa042739)

Acute Coronary Syndrome

Antiplatelets

1988 Aspirin, heparin, or both in UA [15] (http://www.nejm.org/doi/full/10.1056/NEJM198810273191701)

1988 ISIS-2: Aspirin and streptokinase in ACS [16] (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)928334/abstract)
2001 CURE Clopidogrel in UA/NSTEMI [17] (http://www.nejm.org/doi/full/10.1056/NEJMoa010746)
2005 CLARITY-TIMI 28 Clopidogrel in STEMI [18] (http://www.nejm.org/doi/full/10.1056/NEJMoa050522)
2007 TRITON-TIMI 38 Prasurgrel vs. clopidogrel in ACS [19] (http://www.nejm.org/doi/full/10.1056/NEJMoa0706482)
2009 PLATO Ticagrelor vs. clopidogrel in ACS [20] (http://www.nejm.org/doi/full/10.1056/NEJMoa0904327)
2010 CURRENT-OASIS 7 Dosing of clopidogrel and aspirin in ACS [21]
(http://www.sciencedirect.com/science/article/pii/S0140673610610884)
Anticoagulation
1988 Aspirin, heparin, or both in UA [22] (http://www.nejm.org/doi/full/10.1056/NEJM198810273191701)
1996 Heparin in UA: meta-analysis [23] (http://jama.ama-assn.org/content/276/10/811.full)
2004 SYNERGY Enoxaparin vs. UFH in UA/NSTEMI [24] (http://jama.ama-assn.org/content/292/1/45.full)
2006 ACUITY Bivalirudin + GPIIb/IIIa vs. UFH + GPIIb/IIIa in ACS [25] (http://www.nejm.org/doi/full/10.1056/NEJMoa062437)
2006 ExTRACT-TIMI 25 Enoxaparin vs. UFH with fibrinolysis in STEMI [26]
(http://www.nejm.org/doi/full/10.1056/NEJMoa060898)
2006 OASIS-5 Fondaparinux vs. enoxaparin in ACS [27] (http://www.nejm.org/doi/full/10.1056/NEJMoa055443)
2008 ISAR-REACT 3 Bivalirudin vs. UFH in stable angina/UA [28] (http://www.nejm.org/doi/full/10.1056/NEJMoa0802944)
2012 ATLAS ACS-2, TIMI 51 Rivaroxaban in ACS [29] (http://www.nejm.org/doi/full/10.1056/NEJMoa1112277)
-blockers
2005 COMMIT Metoprolol in STEMI [30] (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67661-1/fulltext)
GPIIb/IIIa Inhibitors
2001 ADMIRAL Abciximab plus stenting in ACS [31] (http://www.nejm.org/doi/full/10.1056/NEJM200106213442503)
2006 ACUITY Bivalirudin + GPIIb/IIIa vs. UFH + GPIIb/IIIa in ACS [32] (http://www.nejm.org/doi/full/10.1056/NEJMoa062437)
2008 ISAR-REACT 3 Bivalirudin vs. UFH in stable angina/UA [33] (http://www.nejm.org/doi/full/10.1056/NEJMoa0802944)
2008 HORIZONS-AMI Bivalirudin vs. heparin+GPIIb/IIIa in STEMI [34]
(http://www.nejm.org/doi/full/10.1056/NEJMoa0708191)
PCI/CABG
1999 SHOCK Early PCI/CABG in ACS complicated by cardiogenic shock [35]
(http://www.nejm.org/doi/full/10.1056/NEJM199908263410901)
2003 DANAMI-2 Lytics vs. transfer for PCI in STEMI [36] (http://www.nejm.org/doi/full/10.1056/NEJMoa025142)
2006 BASKET-LATE DES vs. BMS [37] (http://www.sciencedirect.com/science/article/pii/S073510970602523X)
2009 TIMACS Early (<24h) vs. delayed (>36h) intervention in ACS [38] (http://www.nejm.org/doi/full/10.1056/NEJMoa0807986)
2010 BASKET-PROVE DES vs. BMS [39] (http://www.nejm.org/doi/full/10.1056/NEJMoa1009406)
Early invasive vs conservative approach 32% decreased rehosp for ACS, nonsignificant 16% decrease in MI, no change in mortality
compared with conservative strategy.
Lytics
2006 ExTRACT-TIMI 25 Enoxaparin vs. UFH with fibrinolysis in STEMI [40]
(http://www.nejm.org/doi/full/10.1056/NEJMoa060898)
2006 OASIS-6 Fondaparinux vs. UFH in STEMI [41] (http://jama.ama-assn.org/content/295/13/1519.long)
2001 GUSTO-V Combined reteplase + abciximab vs. reteplase in STEMI [42]
(http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)05059-5/fulltext)
2003 DANAMI-2 Lytics vs. transfer for PCI in STEMI [43] (http://www.nejm.org/doi/full/10.1056/NEJMoa025142)
RAAS inhibitors
1994 GISSI-3 Lisinipril in ACS [44] (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract)
1995 ISIS-4 Captopril in ACS [45] (http://www.lancet.com/journals/lancet/article/PIIS0140-6736(95)90865-X/abstract)
2003 EPHESUS Eplerenone in post-MI LV dysfunction [46] (http://www.nejm.org/doi/full/10.1056/NEJMoa030207)
2003 VALIANT ARBS vs. ACE inhibitors post-MI and LV dysfunction [47]
(http://www.nejm.org/doi/full/10.1056/NEJMoa032292)
Statins
2001 MIRACL Atorvastatin statins in post-MI [48] (http://jama.ama-assn.org/content/285/13/1711.long)
2004 PROVE IT-TIMI 22 Intensive atorvastatin vs. moderate pravastatin post-MI [49]
(http://www.nejm.org/doi/full/10.1056/NEJMoa040583#t=abstract)
ICD/CRT
2003 DINAMIT Prophylactic ICD in post-MI LV dysfunction [50] (http://www.nejm.org/doi/full/10.1056/NEJMoa041489)
2003 IRIS Prophylactic ICD early-post-MI [51] (http://www.nejm.org/doi/full/10.1056/NEJMoa0901889#t=abstract)
2009 MADIT-CRT ICD-CRT in LV dysfunction and prolonged QRS [52]
(http://www.nejm.org/doi/full/10.1056/NEJMoa0906431)
Risk Assessment
2000 TIMI Risk stratification in UA/NSTEMI [53] (http://jama.ama-assn.org/content/284/7/835.full)

2012 ROMICAT-II (http://www.wikijournalclub.org/w/index.php?

action=edit&preload=WikiJournalClub%3ADefault+journal+article+page+%28for+beginners%29&editintro=&summary=&nosummary=&prefi
II&create=Create+article): CT coronary angiography in acute chest pain [54]
(http://www.nejm.org/doi/full/10.1056/NEJMoa1201161)

Atrial Fibrillation
Epidemiology
ATRIA Risk factors in AF
Management
2001 ACUTE TEE in AF [55] (http://www.nejm.org/doi/pdf/10.1056/NEJM200105103441901) *363*
2002 AFFIRM Rate vs. rhythm control in chronic AF [56] (http://www.nejm.org/doi/full/10.1056/NEJMoa021328) *1993 cites*
2002 RACE Rate vs. rhythm control in chronic AF
2008 AF-CHF Rate vs. rhythm control in AF and HF [57] (http://www.nejm.org/doi/full/10.1056/NEJMoa0708789) *421*
2010 RACE II Lenient vs. strict rate control in permanent AF [58] (http://www.nejm.org/doi/full/10.1056/NEJMoa1001337)
Antiarrhythmics
2000 CTAF Amiodarone vs. sotalol or propafenone in AF [59] (http://www.nejm.org/doi/pdf/10.1056/NEJM200003303421302)
2005 SAFE-T Amiodarone vs. sotalol in AF
2007 ADONIS Dronedarone for maintenance of SR in AF [60] (http://www.nejm.org/doi/full/10.1056/NEJMoa054686) *341*
2009 ATHENA Dronedarone in AF [61] (http://www.nejm.org/doi/full/10.1056/NEJMoa0803778) *479*
Anticoagulation
1989 AFASAK Warfarin vs. aspirin in chronic AF [62] (http://www.sciencedirect.com/science/article/pii/S0140673689912002)
*1030*
1990 BAATAF Warfarin in chronic AF [63] (http://www.nejm.org/doi/pdf/10.1056/NEJM199011293232201) *911 cites*
1991 SPAF I Warfarin vs. aspirin in chronic AF
1992 SPINAF Warfarin in chronic AF [64] (http://www.nejm.org/doi/pdf/10.1056/NEJM199211123272002) *827*
1994 SPAF II Warfarin vs. aspirin in AF [65] (http://www.sciencedirect.com/science/article/pii/S0140673694915776) *809*
1996 SPAF III Adjusted-dose warfarin vs. low-dose warfarin plus aspirin in AF [66]
(http://www.sciencedirect.com/science/article/pii/S0140673696034873#) *858*
2000 HAEST LMWH vs. aspirin in AF [67] (http://www.sciencedirect.com/science/article/pii/S0140673600020857#)
2003 SPORTIF III Ximelagatran vs. warfarin in AF [68] (http://www.sciencedirect.com/science/article/pii/S0140673603148416)
*662*
2006 ACTIVE W Warfarin vs. aspirin plus clopidogrel in AF [69]
(http://www.sciencedirect.com/science/article/pii/S0140673606688454#) *1996*
2007 BAFTA Warfarin vs. aspirin for AF in elderly [70] (http://www.sciencedirect.com/science/article/pii/S0140673607612331#)
*508*
2009 ACTIVE Plavix and aspirin in AF [71] (http://www.nejm.org/doi/full/10.1056/NEJMoa0901301) *427*
2009 RE-LY Dabigatran vs. coumadin in AF [72] (http://www.nejm.org/doi/full/10.1056/NEJMoa0905561) *1577*
2011 ROCKET AF Rivaroxaban vs. warfarin in AF [73] (http://www.nejm.org/doi/full/10.1056/NEJMoa1009638) *444*
2011 ARISTOTLE Apixaban vs. warfarin in AF [74] (http://www.nejm.org/doi/full/10.1056/NEJMoa1107039) *388*
2011 AVERROES Apixaban vs. aspirin in AF [75] (http://www.nejm.org/doi/full/10.1056/NEJMoa1007432) *321*

CHF
Hydralazine & nitrates
1986 V-HeFT ISDN/hydralazine in CHF [76] (http://www.nejm.org/doi/full/10.1056/NEJM198606123142404)
1991 V-HeFTII Hydralazine & nitrates vs. Ace-inhibitors in CHF [77]
(http://www.nejm.org/doi/full/10.1056/NEJM199108013250502)
2004 A-HeFT ISDN/hydralazine in blacks with NYHA class III-IV CHF [78]
(http://www.nejm.org/doi/full/10.1056/NEJMoa042934)
-blockers
2000 MERIT-HF Metoprolol XL in CHF [79] (http://jama.ama-assn.org/content/283/10/1295.long)[80]
(http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2899%2904440-2/fulltext)
2002 COPERNICUS Carvedilol in severe CHF [81] (http://circ.ahajournals.org/content/106/17/2194.full)
2003 COMET Carvedilol vs. metoprolol tartrate in CHF (Lancet 2003;362:7)
Ace-inhibitors
1987 CONSENSUS Enalapril in NYHAIV CHF [82] (http://www.nejm.org/doi/full/10.1056/NEJM198706043162301)
1991 SOLVD Enalapril in CHF with EF <35% [83] (http://www.nejm.org/doi/full/10.1056/NEJM199108013250501)
1992 SAVE Captopril in post-MI CHF with EF 40%[84] (http://www.nejm.org/doi/full/10.1056/NEJM199209033271001)
1992 SOLVD-PEnalapril in aSx CHF with EF 35%[85] (http://www.nejm.org/doi/full/10.1056/NEJM199209033271003)
ARBs
2001 Val-HeFT Valsartan in CHF [86] (http://www.nejm.org/doi/full/10.1056/NEJMoa010713)

2003 CHARM-Added Candesartan added to ACE inhibitors in CHF [87]

(http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14283-3/fulltext)
2003 CHARM-Preserved Candesartan added to ACE inhibitors in CHF [88]
(http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14285-7/fulltext)
2003 CHARM-Alternative Candesartan alone in CHF [89] (http://www.thelancet.com/journals/lancet/article/PIIS01406736(03)14284-5/fulltext)
2008 I-PRESERVE Irbesartan in HFPEF [90] (http://www.nejm.org/doi/full/10.1056/NEJMoa0805450)
2009 HEAL Higher doses of Losartan in CHF [91] (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)619139/fulltext)
Aldosterone antagonists
1999 RALES Spironolactone in NYHA III/IV CHF & EF <= 35% [92]
(http://www.nejm.org/doi/full/10.1056/NEJM199909023411001)
2003 EPHESUS Eplerenone in post-MI patients with LV dysfunction EF40% [93]
(http://www.nejm.org/doi/full/10.1056/NEJMoa030207)
2011 EMPHASIS-HF Eplerenone in NYHA II CHF with LVEF <30% [94]
(http://www.nejm.org/doi/full/10.1056/NEJMoa1009492)
Digoxin
1997 DIG Digoxin in CHF with LVEF 45%[95] (http://www.nejm.org/doi/full/10.1056/NEJM199702203360801)
ICD
2002 MADIT-II ICD in post-MI CHF with LVEF 30 [96] (http://www.nejm.org/doi/full/10.1056/NEJMoa013474)
2004 DEFINITE ICD in severe, nonischemic dilated cardiomyopathy [97] (http://www.nejm.org/doi/full/10.1056/NEJMoa033088)
2004 DINAMIT Prophylactic ICD post-MI [98] (http://www.nejm.org/doi/full/10.1056/NEJMoa041489)
2005 SCD-HeFT Amiodarone vs. ICD in CHF [99] (http://www.nejm.org/doi/full/10.1056/NEJMoa043399)
2005 CARE-HF CRT in NYHA III-IV CHF [100] (http://www.nejm.org/doi/full/10.1056/NEJMoa050496)
2009 IRIS Prophylactic ICD post-MI [101] (http://www.nejm.org/doi/full/10.1056/NEJMoa0901889)
2009 MADIT-CRT ICD-CRT in NYHA I-II CHF with EF < 30%, prolonged QRS [102]
(http://www.nejm.org/doi/full/10.1056/NEJMoa0906431)
2009 TIME-HF BNP- vs. Symptom-guided therapy in CHF [103] (http://jama.ama-assn.org/content/301/4/383.full)
Volume management
2007 UNLOAD Ultrafiltration in CHF (JACC 2007;49:675)
2010 DOSE Continuous vs. intermittent lasix
2012 CARRESS-HF Ultrafiltration in decompensated HF [104] (http://www.nejm.org/doi/full/10.1056/NEJMoa1210357)
Nesiritide
2002 ASCEND-HF Nesiritide in CHF [105] (http://www.nejm.org/doi/full/10.1056/NEJMoa1100171)
LVAD
2001 REMATCH LVAD in HF [106] (http://www.nejm.org/doi/pdf/10.1056/NEJMoa012175)
2006 LVAD in CHF [107] (http://www.nejm.org/doi/full/10.1056/NEJMoa053063)
2009 HEARTMATE II LVAD in advanced CHF [108] (http://www.nejm.org/doi/full/10.1056/NEJMoa0909938)
Fish oil
2008 GISSI-HF FIsh oil in CHF [109] (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61239-8/fulltext)
Telemonitoring
2011 CHAMPION Wireless PA monitoring in CHF [110] (http://www.thelancet.com/journals/lancet/article/PIIS01406736(11)60101-3/abstract)

Cardiac Risk Assessment

2004 CARP Revascularization before elective vascular surgery [111] (http://www.nejm.org/doi/full/10.1056/NEJMoa041905)

2008 POISE Perioperative metoprolol succinate [112] (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)606017/fulltext)
2009 DECREASE Preoperative fluvastatin [113] (http://www.nejm.org/doi/full/10.1056/NEJMoa0808207)
2009 DECREASE-V Revascularization in high-risk patients before major vascular surgery [114]
(http://www.sciencedirect.com/science/article/pii/S0002914908021735)
2012 VISION (http://www.wikijournalclub.org/w/index.php?
action=edit&preload=WikiJournalClub%3ADefault+journal+article+page+%28for+beginners%29&editintro=&summary=&nosummary=&prefi
Post-op troponin for predicting mortality [115] (http://www.ncbi.nlm.nih.gov/pubmed/22706835)

Endocarditis
2012 EASE Early surgery for endocarditis [116] (http://www.nejm.org/doi/full/10.1056/NEJMoa1112843)
Retrieved from "http://wikijournalclub.org/w/index.php?title=WikiJournalClub:List_of_landmark_papers/Cardiology&oldid=17560"

This page was last modified on 12 August 2015, at 18:35.

This page has been accessed 14,584 times.